Cancer in cadaver kidney transplant patients.
Eighty-nine de novo malignant tumors were diagnosed among 2339 Scandinavian patients who received 3203 cadaver kidney transplants between 1956 and 1978. In 72 of these cases the contralateral kidney from the same donor was also used for transplantation. Each of these 72 pairs consisted of a tumor patient and a control patient with the same prospective specific donor-induced oncogenic factor, almost identical ABO and HLA matching, and the same period of observation. There was no difference between the groups in terms of number of transplantations per patient, occurrence of antibodies, sex or age differences between donor and recipient, immunosuppressive therapy, cumulative dose of drugs, numbers of rejection episodes, incidence of viral infections, duration of dialysis, or number of pretransplant blood transfusions. The tumor patients were older than the control patients and had a higher incidence of chronic interstitial nephritis and a higher death rate, but their survival time was not shorter.